We are live on
!
Find out more
OCMI
Oaktop Capital Management II Portfolio holdings
AUM
$1.34B
1-Year Est. Return
114.5%
This Fund
S&P 500
This Quarter
Est. Return
-17%
1 Year Est. Return
+114.5%
3 Year Est. Return
+223.73%
5 Year Est. Return
+264.71%
10 Year Est. Return
+1,370.55%
AUM
$327M
AUM Growth
-$54.4M
(-14%)
Cap. Flow
+$16.5M
Cap. Flow
% of AUM
5.05%
Top 10 Holdings %
Top 10 Hldgs %
92.1%
Holding
20
New
2
Increased
3
Reduced
2
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$7.64M |
| 2 |
Broadcom
AVGO
|
+$4.23M |
| 3 |
GRMN
Garmin
GRMN
|
+$4.07M |
| 4 |
Sonos
SONO
|
+$3.09M |
| 5 |
Aspen Aerogels
ASPN
|
+$2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CEVA Inc
CEVA
|
+$4.51M |
| 2 |
BBBY
Bed Bath & Beyond
BBBY
|
+$16.2K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 66.88% |
| 2 | Healthcare | 15.4% |
| 3 | Industrials | 5.34% |
| 4 | Consumer Discretionary | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Lam Research
LRCX
$374B
| $76M | 23.25% |
3,165,040
| – | – |
|
2
KLA
KLAC
$241B
| $57.6M | 17.63% |
4,007,500
| – | – |
|
|
3
Bristol-Myers Squibb
BMY
$131B
| $37.9M | 11.6% |
679,991
+125,000
| +23% | +$7.64M |
|
|
MXIM
4
DELISTED
Maxim Integrated Products
MXIM
| $36.1M | 11.05% |
742,375
| – | – |
|
5
Progress Software
PRGS
$1.63B
| $19.6M | 6% |
612,526
| – | – |
|
6
eGain
EGAN
$183M
| $18.6M | 5.69% |
2,536,843
| – | – |
|
|
7
Aspen Aerogels
ASPN
$376M
| $17.4M | 5.34% |
2,839,758
+246,486
| +10% | +$2M |
|
|
8
CEVA Inc
CEVA
$912M
| $15.7M | 4.82% |
631,377
-162,459
| -20% | -$4.51M |
|
|
VMW
9
DELISTED
VMware, Inc
VMW
| $11.2M | 3.43% |
92,500
| – | – |
|
10
PetMed Express
PETS
$42.3M
| $10.8M | 3.29% |
373,675
| – | – |
|
11
Dell
DELL
$263B
| $5.56M | 1.7% |
277,441
| – | – |
|
|
12
Sonos
SONO
$1.75B
| $5.51M | 1.69% |
650,000
+250,000
| +63% | +$3.09M |
|
|
13
Broadcom
AVGO
$1.83T
| $3.56M | 1.09% |
+150,000
| New | +$4.23M |
|
|
GRMN
14
Garmin
GRMN
$57.1B
| $3.37M | 1.03% |
+45,000
| New | +$4.07M |
|
15
State Street Energy Select Sector SPDR ETF
XLE
$39.2B
| $2.91M | 0.89% |
200,000
| – | – |
|
16
Intel
INTC
$466B
| $1.79M | 0.55% |
33,010
| – | – |
|
|
BMY.RT
17
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $1.35M | 0.41% |
354,991
| – | – |
|
|
AXDX
18
DELISTED
Accelerate Diagnostics
AXDX
| $1.29M | 0.4% |
15,500
| – | – |
|
19
Anika Therapeutics
ANIK
$243M
| $361K | 0.11% |
12,500
| – | – |
|
|
BBBY
20
Bed Bath & Beyond
BBBY
$470M
| $123K | 0.04% |
29,841
-2,984
| -9% | -$16.2K |
|
Similar funds
FFW
NEWAS
BFMH
HAM
4WM
WA
VHAM
AWA
Oaktop Capital Management II's Q1 2020 Portfolio in Review
As of Q1 2020, Oaktop Capital Management II held 20 positions worth $327M, down 14% from $381M the previous quarter. Its ten largest holdings account for 92% of the portfolio.
Oaktop Capital Management II deployed $16.5M of net new capital in Q1 2020, opening 2 new positions and adding to 3 existing holdings. Its largest new stake was Broadcom: 150,000 shares worth $3.56M.
By sector, the portfolio is most concentrated in Technology at 67% of assets, down from 68% a quarter earlier, followed by Healthcare and Industrials.
On the sell side, the largest reduction was CEVA Inc, an estimated $4.51M trimmed.
- Oaktop Capital Management II's largest Q1 2020 buy was Broadcom: 150,000 shares worth $3.56M.
- Oaktop Capital Management II added most to Bristol-Myers Squibb in Q1 2020, an estimated $7.64M increase.
- Oaktop Capital Management II's biggest Q1 2020 reduction was CEVA Inc, cutting an estimated $4.51M.
- Oaktop Capital Management II's ten largest holdings make up 92% of its $327M portfolio in Q1 2020.
- Oaktop Capital Management II opened 2 new positions and closed 0 in Q1 2020.
- Oaktop Capital Management II's portfolio value fell 14% quarter-over-quarter to $327M.
Based on Oaktop Capital Management II's 13F filing for Q1 2020, filed 12 May 2020.